It has been a good year for Alexion Pharmaceuticals (NASDAQ: ALXN ) earnings
are up, its star drug Solaris is coming on strong and the company's stock is
on a tear. The stock's performance has moved it to the head of the class among
its peers in the biopharmaceutical niche. But does ALXN have what it takes to go
the distance? Biopharmaceuticals, which are drugs created primarily from
antibodies or living organisms like viruses and bacteria, are one of the most
promising niches in pharmaceuticals because these drugs can treat rare and
difficult conditions. ALXN's peers in the biopharmaceutical space include
Amgen (NASDAQ: AMGN ), Allergan (NYSE: AGN ) and Roche/c (PINK: RHHBY ). All
investors dream of being able to predict a stock sector boom and better yet,
picking the next big winner. After all, who wouldn't have liked to say "I
bought Amazon (NASDAQ: AMZN ) back in '97 at $1.50"? Of course, for every
Amazon, there were scores of two-year wonders like WebVan
No comments:
Post a Comment